Search for Sandoz Inc and
    1. December 11, 2013

      J&J and Novartis mull appeal against €16m EU fines

      Johnson & Johnson and Novartis are considering whether to appeal against EU antitrust fines of €16m imposed this week for...

    2. August 8, 2013

      Surgery needed to keep Novartis in shape

      The strength of Novartis is that it does what a big drug company should do: it makes original drugs that cure or ease the...

    1. July 4, 2013

      China launches drug pricing probe

      China’s drug pricing authority has launched a wide-ranging probe into the costs of medicines at 60 domestic and...

    2. April 28, 2013

      Teva discovers sophisticated fakes of popular drug

      Leading generic drugmakers are stepping up quality inspections in Europe after unearthing a sophisticated counterfeiting...

    3. February 18, 2013

      Novartis: Vasella-tions

      Daniel Vasella has always put a high price on his worth, and so has the board of Novartis. As chairman and chief executive...

    4. May 3, 2012

      Sandoz gains dermatology lead with Fougera

      Novartis’s generic drugs division Sandoz has agreed to buy Fougera Pharmaceuticals for $1.53bn in cash in a deal that...

    5. April 24, 2012

      Novartis profits hit by US plant closure

      Novartis reported slipping sales and sharply lower net profits in the first quarter, as long-term pressures on health...

    6. January 25, 2012

      Novartis upbeat despite end of Diovan patent

      Novartis forecast it would maintain sales and suffer only potentially slightly lower operating profits this year, despite...

    7. November 11, 2011

      Art and design: What you can buy when you know the right people

      The jewellery and watch world has seen a series of art and design exhibitions lately. Some take a lateral approach, offering...

    8. September 9, 2011

      Movements: Emotions run high amid timepiece turmoil

      Seldom in the secretive world of Swiss watchmaking has a dispute become as public as the row that has erupted over movements...

    9. February 8, 2011

      Clariant poised for expansion

      Caught between volatile raw materials prices and spiralling competition, Europe’s speciality chemicals companies have...

    10. January 27, 2011

      Novartis confident despite market pressures

      Novartis remains optimistic about the current year, in spite of intensifying pricing pressure in many markets as stretched...

    11. October 21, 2010

      Novartis results lifted by new products

      Novartis demonstrated the benefits of continuing efficiency improvements and a strong pipeline of new drugs, as the Swiss...

    12. May 25, 2010

      GSK keeps up fight for control of drug

      When a feisty Indian generics company took on GlaxoSmithKline in its home market six years ago it won the first battle in a...

    13. May 24, 2010

      GSK keeps up fight for control of drug

      When a feisty Indian generics company took on GlaxoSmithKline in its home market six years ago it won the first battle in a...

    14. April 20, 2010

      Vectura hit by Sandoz move

      Vectura Group dropped 6.8 per cent to 41p after its development partner acquired a rival inhaler maker.Novartis's Sandoz...

    15. March 27, 2010

      Europe halts sale of Indian-sourced drug

      European regulators have halted sales of several variants of clopidogrel, a drug widely used to stop blood clots, in a move...

    16. January 27, 2010

      Novartis in stealthy pursuit of change

      Daniel Vasella may be among the more youthful chief executives in the international pharmaceutical industry - but he is also...

    17. January 26, 2010

      Novartis in stealthy pursuit of change

      Split decision: corporate governance lobbyists welcomed the resignation of Daniel Vasella (right). Joe Jimenez (left) will...

    18. October 8, 2009

      French generic drug raids point to wider probe

      The breadth of the European Commission’s antitrust probe into the generic industry launched this week suggests it extends...

    19. June 11, 2009

      Generic drugmakers adapt to survive

      The prospects seem bright right now for those making lower-cost generic drugs. Healthcare systems are increasingly looking...

    20. May 21, 2009

      Pfizer in tie-up with 2 Indian companies

      Pfizer, the world’s largest pharmaceuticals company, on Wednesday sharply accelerated its presence in generic drugs around...

    21. May 21, 2009

      Cancer drug push at Novartis

      Novartis yesterday said it would spend €925m ($1.3bn) to expand into speciality cancer drugs in an effort to strengthen its...

    22. May 20, 2009

      Cancer drug push at Novartis

      Novartis on Wednesday said it would spend €925m ($1.3bn) to expand into speciality cancer drugs in an effort to strengthen...

    23. May 4, 2009

      Vectura benefits from moving up ranks

      As the economy shrinks, and businesses fail, Britain’s traditionally risky biotech sector has been a surprising source of...

    24. March 10, 2009

      Hassan has seen string of deals

      Merck and its chief executive Richard Clark may be novices in large-scale mergers, but Fred Hassan, the head of...

    25. October 21, 2008

      Novartis paves way for chairman’s successor

      The board of Novartis on Monday slackened the strong grip Daniel Vasella, its veteran chairman and chief executive, holds...

    26. October 21, 2008

      New post at Novartis paves way for chairman's successor

      The board of Novartis yesterday slackened the strong grip Daniel Vasella, its veteran chairman and chief executive, holds...

    27. October 21, 2008

      New post at Novartis paves way for chairman's successor

      The board of Novartis yesterday slackened the strong grip Daniel Vasella, its veteran chairman and chief executive, holds...

    28. September 22, 2008

      Setback for Sandoz as WHO points to plant problems

      Sandoz, the generic drugs arm of Novartis of Switzerland, risks losing World Health Organisation authorisation to sell some...

    29. September 21, 2008

      WHO to warn customers over Sandoz drugs

      Sandoz, the generic drugs arm of Novartis of Switzerland, risks losing World Health Organisation authorisation to sell some...

    30. September 16, 2008

      BASF/Ciba

      Ciba is in a sandwich. The Swiss speciality chemicals producer is much smaller than both its raw materials suppliers and...

    31. September 15, 2008

      BASF/Ciba

      Ciba is in a sandwich. The Swiss speciality chemicals producer is much smaller than both its raw materials suppliers and its...

    32. September 8, 2008

      Swiss chemicals groups hit crossroads

      The Rhine flows broad and slow at Basel, the Swiss city whose fortunes were based in chemicals. But Ciba and Clariant, the...

    33. July 2, 2008

      AstraZeneca sees off generic rival

      Shares in AstraZeneca jumped 6 per cent in early London trading on Wednesday as a US court stopped a generic challenge to...

    34. June 23, 2008

      Africa beckons for serial entrepreneurs

      Dov and Anat Bar-Gera call themselves "serial entrepreneurs" - a term that might bring a smile to their teachers at Insead,...

    35. June 22, 2008

      From Insead to Africa

      Dov and Anat Bar-Gera call themselves “serial entrepreneurs” – a term that might bring a smile to their teachers at Insead,...

    36. April 30, 2008

      Swiss chemist who invented LSD dies

      Albert Hofmann, the Swiss scientist best known for synthesising the hallucinogenic drug LSD, has died aged 102. Hofmann...

    37. November 1, 2007

      Little room for scientists in pharma’s new generation

      Andrew Witty is in good company as he gears up to take charge of the world’s second largest pharmaceutical group next...

    38. September 10, 2007

      Similarity is breeding tougher competition

      As pharmaceutical companies struggle to respond to the intensifying threat to their medicines from generic rivals, one...

    Search for Sandoz Inc and